Rocket Pharmaceuticals Revenue and Competitors

Claim your profile

Location

#4160

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Rocket Pharmaceuticals's estimated annual revenue is currently $4M per year.(i)
  • Rocket Pharmaceuticals received $50.0M in venture funding in November 2018.
  • Rocket Pharmaceuticals's estimated revenue per employee is $21,784
  • Rocket Pharmaceuticals's total funding is $552.8M.

Employee Data

  • Rocket Pharmaceuticals has 185 Employees.(i)
  • Rocket Pharmaceuticals grew their employee count by 24% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.1M3343%N/AN/A
#2
$32.9M212-10%N/AN/A
#3
$0.5M6-14%$10MN/A
#4
$7.5M3911%$51.6MN/A
#5
$4.3M31-9%$3.3MN/A
#6
$6M3922%N/AN/A
#7
$4.2M27-16%N/AN/A
#8
$0.7M9-18%$3.2MN/A
#9
$57M3684%N/AN/A
#10
$115.6M9941%$61MN/A

Rocket Pharmaceuticals, Ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. We are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. We have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. Ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. For more information, please visit www.rocketpharma.com.

keywords:N/A

$552.8M

Total Funding

185

Number of Employees

$4M

Revenue (est)

24%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Rocket Pharmaceuticals News

2022-04-17 - Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Expected to ...

Zero analysts have issued estimates for Rocket Pharmaceuticals' earnings, with the highest EPS estimate coming in at ($0.63) and the lowest...

2022-04-13 - Rocket Pharmaceuticals (NASDAQ:RCKT) Earns Buy Rating ...

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Rating)'s stock had its “buy” rating reaffirmed by Needham & Company LLC in a report issued on...

2022-03-30 - Rocket Pharmaceuticals to Present at Upcoming Investor ...

Rocket Pharmaceuticals to Present at Upcoming Investor Conferences. March 29, 2022 07:00 AM Eastern Daylight Time. CRANBURY, N.J.--(BUSINESS WIRE)--Rocket...

2021-03-22 - Rocket Pharmaceuticals Announces Updated Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency

CRANBURY, N.J.--(BUSINESS WIRE)--Mar 22, 2021-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces updated preliminary clinical data from its Phase 1 trial of R ...

2021-03-09 - Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I

CRANBURY, N.J.--(BUSINESS WIRE)--Mar 9, 2021-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the U.S. Food and Drug Administration (FDA) has granted R ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$30.5M18534%N/A
#2
$46.4M1855%N/A
#3
$25.9M18517%$658.3M
#4
$29.5M185N/AN/A
#5
$29.5M185N/AN/A

Rocket Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2018-11-27$50.0MUndisclosedBofA Merrill LynchArticle